Aggressive management of newly-diagnosed young-onset type 2 diabetes mellitus with a combination of empagliflozin and linagliptin in a single pill

Recent years have seen relative increases in the incidence and prevalence of type 2 diabetes mellitus (T2DM) in children, adolescents and young adults aged <40years. T2DM in younger people, referred to as young-onset T2DM, has a more rapid deterioration of β-cell function than observed in late-onset T2DM. Young individuals with T2DM are also at an elevated risk of developing microvascular and macrovascular complications compared to those with type 1 diabetes mellitus.